Home > Insider Trading > Filing (0000899243-22-021957)

Filing Details

Accession Number:: 0000899243-22-021957
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-06-10 17:20:57
Reporting Period:: 2022-06-08

Accepted Time:: 2022-06-10 17:20:57
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1503802	Karyopharm Therapeutics Inc.	KPTI	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1270734	Deepika Pakianathan	C/O Delphi Ventures, 63 Bovet Road, Suite 351 San Mateo CA 94402		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-06-08	322,825	$6.50	1,918,298	No	4	S	Indirect	See footnote
Common Stock	Disposition	2022-06-08	3,152	$6.50	18,731	No	4	S	Indirect	See footnote
Common Stock	Disposition	2022-06-09	209,455	$6.18	1,708,843	No	4	S	Indirect	See footnote
Common Stock	Disposition	2022-06-09	2,045	$6.18	16,686	No	4	S	Indirect	See footnote
Common Stock	Disposition	2022-06-10	1,294	$6.00	1,707,549	No	4	S	Indirect	See footnote
Common Stock	Disposition	2022-06-10	13	$6.00	16,673	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Footnotes

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.
The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.